openPR Logo
Press release

Actos Bladder Cancer Link Has More Patients Seeking Legal Help

11-30-2011 01:56 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen, LLP

Los Angeles, CA, November 28, 2011 – As more Actos users are discovering the link between the Type 2 diabetes drug and bladder cancer, the need for experienced legal representation has increased. Prominent national law firm Nadrich & Cohen, LLP is now offering free initial case evaluations for Actos users who’ve experienced serious side effects, including bladder cancer.

The U.S. Food and Drug Administration issued the first warnings about possible Actos side effects in September 2010 after a ten-year research study indicated the potential for an increased risk of bladder cancer among users of the drug. In June of 2011, health officials in France and Germany halted the sale of Actos based on information which also suggested a higher likelihood of bladder cancer among Actos users.

While the FDA has yet to pull Actos off the market in the U.S., new warnings for the drug were issued following the European recall in June. In an official statement, the FDA warned that Actos users who remained on the drug for more than a year may have a greater chance of developing bladder cancer. The warning also urged Actos users to consult their doctor if they began experiencing unusual symptoms, such as blood in the urine, painful urination or severe lower back pain.

Following these announcements, a number of Actos side effects lawsuits began making their way into federal court. In response to the growing number of Actos complaints, Nadrich & Cohen opted to create the www.SideEffectActos.com website to provide concerned Actos users with the latest information, news and updates surrounding the bladder cancer allegations. Visitors to the site may also complete an online form to submit their information to one of the firm’s Actos side effects injury experts.

In December, the U.S. Judicial Panel on Multidistrict Litigation will hear arguments as to whether the approximately 1,000 or so Actos lawsuits that have already been filed should be consolidated into a multidistrict litigation for pretrial proceedings. Takeda Pharmaceuticals, the Japanese maker of Actos, has yet to comment on the lawsuits or the allegations they contain.

If you or someone you love has developed bladder cancer symptoms after taking Actos, the law firm of Nadrich & Cohen, LLP urges you to contact their Injury Hotline immediately at 1-800-722-0765. Depending on the laws in your state, you may have a very specific time frame in which to file an Actos injury lawsuit to seek compensation for your injuries. The Actos legal team at Nadrich & Cohen is currently investigating claims from patients in all 50 states and they are eager to assist you in protecting your rights. Visit www.SideEffectActos.com to get more information about Actos and the symptoms of bladder cancer or to schedule your free initial case evaluation today.
###

Contact:

Jennifer Poole

National Client Intake Coordinator

Nadrich & Cohen, LLP

12100 Wilshire Blvd. Suite 1250

Los Angeles, CA 90025

800-718-4658

www.PersonalInjuryLawCal.com

Nadrich & Cohen, LLP is a prominent national law firm specializing in handling personal injury claims. We are currently assisting clients in all 50 states with claims arising from Actos side effects, Transvaginal mesh injuries, Yaz side effects, car accidents, motorcycle accidents, DePuy hip implants and birth defects caused by Zoloft, Paxil and similar drugs.

12100 Wilshire Blvd
Suite 1250
Los Angeles, CA 90025
800-718-4658
jpoole@personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Actos Bladder Cancer Link Has More Patients Seeking Legal Help here

News-ID: 202404 • Views: 1658

More Releases from Nadrich & Cohen, LLP

Johnson & Johnson Defends Withdrawal of PMA for Rejected Hips
Nadrich & Cohen, LLP reports that Johnson & Johnson is defending its withdrawal of a PMA for a rejected metal hip device that was reportedly sold overseas. Los Angeles, CA, February 16, 2012 – The Johnson & Johnson Company is facing more criticism after a recent New York Times article revealed that the company continued to market a metal hip resurfacing system overseas, despite the fact that the FDA failed to
Actos Bladder Cancer Lawsuits Continue to Mount as Attorneys Push for Consolidat …
With new Actos bladder cancer lawsuits being filed every day, the plaintiffs and their attorneys are urging for the consolidation of these cases. Some 3500 Actos lawsuits have been filed in state and federal courts across the country, including Illinois, New York, New Jersey, Ohio and California. The law firm of Nadrich & Cohen LLP is currently investigating claims from Actos users in all 50 states who claim they developed
New Actos Bladder Cancer Resource Center Offers Answers to Concerned Patients
Los Angeles, CA, December 6, 2011 -- Nadrich & Cohen LLP, a prominent national law firm, has established a new website geared towards helping Actos users who developed bladder cancer after taking the drug. Visitors to the new site, www.SideEffectActos.com, can find the latest updates, news and information on the Actos bladder cancer litigation. The link between Actos and bladder cancer first came to light in September 2010, when the
New Vaginal Mesh Safety Recommendations Issued
National law firm Nadrich & Cohen LLP is endorsing new recommendations issued by the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) regarding the use of transvaginal mesh to treat pelvic organ prolapse in certain women. In a joint statement, the two organizations called for physicians to limit their use of vaginal mesh only to high-risk women for whom other treatment methods would not be

All 5 Releases


More Releases for Actos

Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the
More Actos Bladder Cancer Lawsuits Filed in Los Angeles
Nadrich & Cohen LLP reports that new lawsuits have been filed in Los Angeles against the maker of Actos by two patients who allege the drug caused bladder cancer. Los Angeles, CA, December 30, 2011 – As Takeda Pharmaceuticals continues to battle litigation over its Type 2 diabetes drug Actos, three additional lawsuits were filed in a Los Angeles court. The newest claims join the thousands of other Actos lawsuits that
Nadrich & Cohen Now Reviewing Actos Bladder Cancer Claims
Los Angeles, CA, December 12, 2011 – Nadrich & Cohen LLP, a prominent national law firm, is now reviewing claims from Actos users in all 50 states who developed bladder cancer after taking the drug. In an effort to connect with even more Actos users across the country, the firm has established an online resource center at www.SideEffectActos.com. Actos was approved by the U.S. Food and Drug Administration to treat adults
FDA Delays Actos Combo Drug Review as Actos Bladder Cancer Lawsuits Continue to …
Los Angeles, CA, December 9, 2011 – As Actos bladder cancer lawsuits continue to mount, the Food and Drug Administration has opted to delay its review of a new Type 2 diabetes drug that combines Actos with algoliptin. The FDA’s decision represents another blow to Japanese drug-maker Takeda Pharmaceuticals, who may face as many 10,000 lawsuits from Actos users who claim they developed bladder cancer after taking the drug. The
Actos Bladder Cancer Lawsuits Expected to Top 10,000
Los Angeles, CA, December 2, 2011 --- The number of lawsuits stemming from Actos bladder cancer claims may reach more than 10,000, according to a Bloomberg report. In response, national law firm Nadrich & Cohen, LLP has launched a new Actos bladder cancer resource website to assist patients in filing their claims. Visitors to www.SideEffectActos.com can read up on the link between Actos and bladder cancer, get the latest updates